FDA says Aldara "approvable" for superficial basal cell carcinoma Tx

Source: www.pharmalive.com 3M has received an ?approvable? letter from the FDA in response to its supplemental new drug application on Aldara (imiquimod cream), 5 percent, for treatment of superficial basal cell carcinoma, a common form of non-melanoma skin cancer.

Related Videos
Related Content

Metal Implants Can Lead to Allergic Contact Dermatitis

March 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Highlights from AAD 2023

March 23rd 2023

Metal Implants Can Lead to Allergic Contact Dermatitis

March 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Highlights from AAD 2023

March 23rd 2023

Metal Implants Can Lead to Allergic Contact Dermatitis

March 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Highlights from AAD 2023

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.